June 15, 2018, European League Against Rheumatism The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that canakinumab significantly reduced the rate of gout by more than half compared to placebo, regardless of baseline serum urate level. “These are significant results as they add to the evidence base...